AP2374A - Isoxazoline derivative and novel process for its preparation. - Google Patents

Isoxazoline derivative and novel process for its preparation.

Info

Publication number
AP2374A
AP2374A AP2007004103A AP2007004103A AP2374A AP 2374 A AP2374 A AP 2374A AP 2007004103 A AP2007004103 A AP 2007004103A AP 2007004103 A AP2007004103 A AP 2007004103A AP 2374 A AP2374 A AP 2374A
Authority
AP
ARIPO
Prior art keywords
preparation
novel process
isoxazoline derivative
isoxazoline
derivative
Prior art date
Application number
AP2007004103A
Other languages
English (en)
Inventor
Tae Ho Heo
Jae-Hoon Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Application granted granted Critical
Publication of AP2374A publication Critical patent/AP2374A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AP2007004103A 2005-02-26 2006-02-21 Isoxazoline derivative and novel process for its preparation. AP2374A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20050016203 2005-02-26

Publications (1)

Publication Number Publication Date
AP2374A true AP2374A (en) 2012-03-07

Family

ID=36927605

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004103A AP2374A (en) 2005-02-26 2006-02-21 Isoxazoline derivative and novel process for its preparation.

Country Status (28)

Country Link
US (1) US8044080B2 (no)
EP (1) EP1851214B1 (no)
JP (1) JP4961357B2 (no)
KR (1) KR100774999B1 (no)
CN (1) CN101128459B (no)
AP (1) AP2374A (no)
AR (1) AR055314A1 (no)
AU (1) AU2006217293B2 (no)
BR (1) BRPI0607330B1 (no)
CA (1) CA2598347C (no)
DK (1) DK1851214T3 (no)
EA (1) EA013005B1 (no)
ES (1) ES2394480T3 (no)
IL (1) IL185226A0 (no)
MA (1) MA29311B1 (no)
MX (1) MX2007010338A (no)
MY (1) MY149181A (no)
NO (1) NO341347B1 (no)
NZ (1) NZ560805A (no)
PE (1) PE20061076A1 (no)
PL (1) PL1851214T3 (no)
PT (1) PT1851214E (no)
SG (1) SG156689A1 (no)
SI (1) SI1851214T1 (no)
TW (1) TWI377205B (no)
UA (1) UA94395C2 (no)
WO (1) WO2006090997A1 (no)
ZA (1) ZA200707202B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101299720B1 (ko) * 2006-08-16 2013-08-28 주식회사 엘지생명과학 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
TW201012816A (en) * 2008-07-11 2010-04-01 Gilead Sciences Inc Method of treatment and pharmaceutical compositions
AR072181A1 (es) * 2008-07-11 2010-08-11 Gilead Sciences Inc Metodo de tratamiento y composiciones farmaceuticas que comprenden (r)-n-((2s,3s)-2-(fluorometil)-2-hidroxi-5-oxo-tetrahidrofuran-3-il)-5-isopropil-3-(isoquinolin-1-il)-4,5-dihidroisoxazol-5-carboxamida y uso
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
BR112015007159A2 (pt) * 2012-09-28 2017-07-04 Bayer Cropscience Ag compostos heterocíclicos que contêm azoto para o controle de doenças de plantas
JP2017095353A (ja) * 2014-03-27 2017-06-01 日本曹達株式会社 イソオキサゾリン−5−カルボキサミド化合物および有害生物防除剤
CN113354708B (zh) * 2017-01-23 2024-05-14 正大天晴药业集团股份有限公司 作为Caspase抑制剂的联环化合物
KR102437095B1 (ko) * 2019-04-19 2022-08-26 주식회사 엘지화학 캐스파제 저해제의 프로드럭
CN113767097B (zh) * 2019-04-30 2025-03-14 株式会社Lg化学 半胱天冬酶抑制剂的前药
US12257341B2 (en) 2019-05-31 2025-03-25 Lg Chem, Ltd. Injectable composition containing prodrug of caspase inhibitors, and preparation method therefor
US20220226306A1 (en) * 2019-05-31 2022-07-21 Lg Chem, Ltd. Composition for caspase inhibitor prodrug injection
CN116113413A (zh) * 2020-08-05 2023-05-12 株式会社Lg化学 胱天蛋白酶抑制剂用于缓解或治疗骨关节炎的用途
KR20220076371A (ko) 2020-11-30 2022-06-08 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
KR102670554B1 (ko) * 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
AU2023208459A1 (en) * 2022-01-24 2024-07-11 Lg Chem, Ltd. Injectable formulation containing isoxazoline derivative
EP4467126A4 (en) 2022-02-23 2025-04-30 LG Chem, Ltd. Injectable formulation containing isoxazoline derivative and method for producing the same
EP4467127A4 (en) 2022-03-24 2025-05-21 LG Chem, Ltd. Injectable preparation comprising isoxazoline derivative, and preparation method therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021600A1 (en) * 1999-09-17 2001-03-29 Lg Chem Investment Ltd. Caspase inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
KR19990079267A (ko) * 1998-04-03 1999-11-05 성재갑 이소옥사졸(또는 이소옥사졸린) 구조를 갖는 파네실 전이효소억제제
WO2001021599A1 (en) * 1999-09-17 2001-03-29 Lg Chemical Ltd. Caspase inhibitor
KR100594544B1 (ko) * 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
TWI256952B (en) * 2003-08-27 2006-06-21 Sk Corp Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021600A1 (en) * 1999-09-17 2001-03-29 Lg Chem Investment Ltd. Caspase inhibitor

Also Published As

Publication number Publication date
CA2598347C (en) 2011-08-02
TW200640918A (en) 2006-12-01
NZ560805A (en) 2010-12-24
EA013005B1 (ru) 2010-02-26
HK1111146A1 (en) 2008-08-01
ES2394480T3 (es) 2013-02-01
KR20060094868A (ko) 2006-08-30
EP1851214B1 (en) 2012-09-05
ZA200707202B (en) 2008-10-29
US8044080B2 (en) 2011-10-25
TWI377205B (en) 2012-11-21
US20080262032A1 (en) 2008-10-23
CA2598347A1 (en) 2006-08-31
BRPI0607330A2 (pt) 2009-09-29
BRPI0607330B1 (pt) 2021-08-03
SI1851214T1 (sl) 2012-11-30
CN101128459A (zh) 2008-02-20
AU2006217293B2 (en) 2012-02-02
DK1851214T3 (da) 2012-10-15
EP1851214A4 (en) 2009-10-28
MY149181A (en) 2013-07-31
IL185226A0 (en) 2008-02-09
SG156689A1 (en) 2009-11-26
AR055314A1 (es) 2007-08-15
PE20061076A1 (es) 2006-12-27
MX2007010338A (es) 2007-10-11
CN101128459B (zh) 2011-10-05
NO20074895L (no) 2007-11-26
UA94395C2 (ru) 2011-05-10
AU2006217293A1 (en) 2006-08-31
KR100774999B1 (ko) 2007-11-09
WO2006090997A1 (en) 2006-08-31
EA200701810A1 (ru) 2008-02-28
JP2008531551A (ja) 2008-08-14
MA29311B1 (fr) 2008-03-03
JP4961357B2 (ja) 2012-06-27
EP1851214A1 (en) 2007-11-07
PT1851214E (pt) 2012-10-18
PL1851214T3 (pl) 2013-03-29
NO341347B1 (no) 2017-10-16

Similar Documents

Publication Publication Date Title
IL185226A0 (en) Isoxazoline derivative and novel process for its preparation
GB0514593D0 (en) Process
EP1937766A4 (en) MODIFIED POLYAMIDES, USES THEREOF AND MANUFACTURING METHOD THEREFOR
GB0513866D0 (en) Process
IL190221A0 (en) Isoxazole derivatives
GB0511460D0 (en) Process
GB0501730D0 (en) Process
GB0506788D0 (en) Process
GB0514698D0 (en) Process
GB0516705D0 (en) Process
GB0519758D0 (en) Novel process
GB0526474D0 (en) Novel process
GB0500604D0 (en) Novel process
ZA200601910B (en) Process for the preparation of organosilances
GB0503694D0 (en) Process
GB0501349D0 (en) Process
GB0501102D0 (en) Process
EP1915131A4 (en) PROCESS
GB0516155D0 (en) Process
GB0501254D0 (en) Process
GB0512662D0 (en) Process
GB0501100D0 (en) Process
EP1915380A4 (en) PROCESS FOR THE SYNTHESIS OF N, N'-DISUBSTITUTED OXABISPIDINES
GB0504079D0 (en) Process
GB0505200D0 (en) Process